MedPath

To compare number of healthy household contacts aged less than 5 years developing Tuberculosis disease after receiving treatment with 3 months isoniazid and rifampicin versus 6 months isoniazid

Phase 3
Registration Number
CTRI/2023/05/052273
Lead Sponsor
Areej bano
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

ALL children less than 5 years of age who are household contacts that is living with bacteriologically confirmed pulmonary tuberculosis patients after ruling out tuberculosis disease in them.

Exclusion Criteria

Children in contact with adults having multidrug resistant tuberculosis or extensively drug resistant tuberculosis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Finding the proportion of children less than 5 years of age who are household contacts <br/ ><br>of pulmonary Tuberculosis patients, developing tuberculosis after receiving treatment with 3 months <br/ ><br>isoniazid and rifampicin versus 6 months isoniazid. <br/ ><br>Timepoint: 2 years
Secondary Outcome Measures
NameTimeMethod
Finding the Non adherence, Adverse drug events and Completion rate in the proportion of children less than 5 years of age who are household contacts of Tuberculosis patient, after receiving treatment for 6 month isoniazid versus 3 month isoniazid and rifampicinTimepoint: 2 years
© Copyright 2025. All Rights Reserved by MedPath